/ Alembic Receives U.S. FDA Approval For Candesartan Cilexetil Tablets ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 21 June 2017

Alembic Pharmaceuticals has received US Food & Drug Administration (U.S. FDA) approval for its Abbreviated New Drug Application (ANDA) for Candesartan Cilexetil Tablets, 32 mg, the company informed the bourses on Wednesday.

Candesartan Cilexetil Tablets are indicated for the treatment of hypertension in adults and children and treatment of heart failure.

Meanwhile, Alembic Pharmaceuticals was trading up by 1.3% at Rs 530 per share at 1114 hours IST on BSE. It hit a high of Rs 545 and a low of Rs 522 so far during the day.

The stock has underperformed the BSE Mid-cap and BSE Healthcare Index over a period of one year. Its closest peers are Alkem Laboratories and Torrent Pharmaceuticals.

Alembic Pharmaceuticals Limited is engaged in developing formulations and active pharmaceutical ingredients (API). The company focuses on therapies such as cardiology, diabetes, gynaecology, gastrointestinal, orthopaedic, dermatology and ophthalmology.

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔ - See more at: http://ways2capital-equitytips.blogspot.in/2017/06/chinese-company-signs-mou-with-adani.html#sthash.3Mqcv7xF.dpuf